Business Context and Reporting Period
This Form 8-K was filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on July 19, 2022, reporting an event that occurred on July 18, 2022. The Company is a biopharmaceutical entity incorporated in Delaware with its principal executive offices in Austin, Texas. Its common stock trades on the Nasdaq Global Market under the symbol "AGLE."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The Company received written notice from Nasdaq stating it no longer complies with the minimum bid price requirement for continued listing. Specifically, the closing bid price of the Common Stock remained below $1.00 per share for 30 consecutive trading days prior to July 18, 2022.
Outlook, Risks, and Management Commentary
- Compliance Period: Nasdaq has granted an initial 180-calendar-day compliance period to regain compliance, ending on January 16, 2023.
- Requirements to Cure: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive trading days prior to the deadline.
- Alternative Options: If the Company fails to comply by the initial deadline, it may be eligible for an additional 180-day period if it elects to transfer to the Nasdaq Capital Market, provided it meets other listing standards (e.g., market value of publicly held shares).
- Risks: Failure to regain compliance within the allotted periods could result in delisting. The Company intends to monitor the stock price and consider available options but notes there is no assurance of regaining compliance or receiving further extensions.
Investor Verification Checklist
- Verify the current closing bid price of AGLE stock to assess progress toward the $1.00 threshold.
- Monitor for any future announcements regarding a reverse stock split or other corporate actions intended to address the bid price deficiency.
- Check for any subsequent filings indicating an election to transfer to the Nasdaq Capital Market.
- Confirm the Company's cash position and runway in separate financial reports (10-K or 10-Q) as this 8-K does not contain financial data.